Fig. 3

Survival analyses in the validation cohort (n = 56). (A) Circle diagrams, distribution of AJCC stage (Fisher’s exact P = 0.86) and patient sex (P = 0.33) over serUM-Px metastatic risk categories. (B) Patients with low serum leptin, and (C) high serum osteopontin at diagnosis had shorter metastasis-free survival. (D) Patients had shorter metastasis-free, and (E) overall survival with increasing serUM-Px metastatic risk category. (F) Metastases appeared up to 16 years after diagnosis, with 65% (11 of 17), 76% (13 of 17), and 94% (16 of 17) of metastases occurring during the first five, ten, and 15 years after diagnosis, respectively. (G) In multivariate Cox regression with patient sex, tumor diameter and serUM-Px metastatic risk category as covariates, serUM-Px was an independent predictor of metastasis (hazard ratio 3.2, 95% CI 1.5 to 6.9). (H) Cumulative incidence of UM related mortality in competing risk analysis. Patients had significantly greater incidence of UM-related mortality with increasing serUM-Px metastatic risk category, but not in death from other causes. For definition of the serUM-Px categories, see Table 2. Colored areas represent 95% confidence intervals